Recent Articles

[Funding alert] Copenhagen-based Orbis Medicines Secures €26Million in Seed Funding

Mar 1, 2024 | By Startup Rise EU

Copenhagen-based Orbis Medicines secures €26million in seed funding. This round was led by global life sciences investor Novo Holdings and European life sciences venture firm Forbion.

Copenhagen-based Orbis Medicines secures €26million in seed funding. This round was led by global life sciences investor Novo Holdings and European life sciences venture firm Forbion.

The funding will support Orbis’ expansion and advancement of its portfolio of next-generation macrocycle drugs it calls ‘nCycles’. Macrocycles are a large and diverse family of compounds with highly desirable therapeutic properties, defined by the presence of a cyclic structure.

Read also - London-based Vitrue Health Secures €3.7 Million in Funding

nCycles are systematically designed by Orbis’ nGen1 platform to be orally bioavailable and membrane permeable, solving decades-long challenges in macrocycle drug design. The Orbis Medicines pipeline includes programs against targets validated by blockbuster biologic drugs, with the goal of providing orbis medicines alternatives that will enable the treatment of many more patients.

In addition, Orbis is developing a pipeline of nCycles for other attractive target classes, both intra- and extra-cellular. Orbis Medicines macrocycle drugs can potentially address a very wide range of diseases based on their ability to target a majority of the potential molecular targets in the body.

Morten Døssing, Chair of the Orbis Board and Partner at Novo Holdings said, “After decades of challenging de novo synthesis, the universe of potential macrocycle targets is now available for exploration. Not only can Orbis reach a wealth of new targets, both inside and outside cells, but we can do this while preserving an oral format to pioneer a new therapeutic class of oral macrocycles. It’s a milestone for drug development, We believe Orbis has the premier chemistry-led approach in the field, which gives us a distinct data advantage. We can generate hundreds of thousands of diverse compounds in record time and immediately apply a range of functional assays in a high-throughput fashion to each individual compound to home in on winners. Establishing this robust, reliable engine for candidate design was crucial for us as we look to bring macrocycle drugs to major patient populations.”

Orbis Medicines was founded in 2021 by the Seeds Investment team of Novo Holdings, with Mr. Døssing as Executive Chair and João Ribas as interim CBO establishing the company’s team and building its corporate strategy. The scientific foundation of Orbis Medicines was developed by Prof. Christian Heinis and Sevan Habeshian at the Swiss Federal Institute of Technology in Lausanne (EPFL).

RECOMMENDED FOR YOU

recomd
Funding
[Funding alert] Resolve Ventures launches €30M Fund for Irish Tech Startups that Tackle Climate Crisis
Startup Rise EU
Dec 1, 2023
recomd
Funding
[Funding alert] UK-based Synaptec Secures £6.5Million in Funding
Team SR
Feb 12, 2024
recomd
Funding
[Funding alert] Hamburg-based Resourcify Secures €14 million Series A Round Funding
Startup Rise EU
Sep 27, 2023

Marco Boorsma, Ph.D., General Partner at Forbion said, “The broad potential of oral macrocycle drugs to address challenging targets untouchable by small molecules, coupled with recent momentum in the field, makes this an incredibly exciting development, With a compelling AI-enabled platform technology, scientific expertise and a clear strategy for growth, Orbis is attracting strong interest for its approach to finally delivering on the promise of this class for medicine. We believe Orbis’s combinatorial approach and ability to continuously generate big data from real compounds gives them an undeniable opportunity to unlock the potential of orally available macrocycle drugs for significantly larger patient populations.”

About Orbis Medicines

Orbis Medicines is a biotechnology company focused on pioneering a new era for oral macrocycle drug discovery. Macrocycles are a large and diverse family of compounds with highly desirable therapeutic properties, defined by the presence of a cyclic structure.

Read also - Cleantech Startup Sonichem Secures €1.4 Million Pre-Series A in Funding

Orbis’ nGen platform is designed to systematically explore the macrocycle chemical space using a highly automated chemistry platform and deliver orbis medicines macrocycle drug candidates – nCycles – suitable for both intra- and extracellular targets.

Recommended Stories for You

story
Funding

[Funding alert] Edinburgh-based Logan Energy Secures £5Million in Funding

Startup Rise EU Feb 29, 2024

story
Denmark

[Funding alert] Copenhagen-based Spektr Secures €5 Million in Funding

Startup Rise EU Feb 21, 2024

story
Recent Articles

[Funding alert] London-based 10x Banking Secures £35Million Funding

Startup Rise EU Jan 18, 2024

story
Recent Articles

[Funding alert] London-based Fintech Startup Lopay Secures £6m Seed Funding

Startuprise Oct 12, 2023

story
Denmark

[Funding alert] Copenhagen-based Fintech Startup Dealflow Raises $700k in Pre-Seed Funding

Startup Rise EU Oct 20, 2023

story
Estonia

[Funding alert] Tallinn-based Inspectle Food’s Secures €400,000 in Funding

Startup Rise EU Dec 12, 2023